<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8211617</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6714</journal-id>
<journal-id journal-id-type="nlm-ta">Prog Neuropsychopharmacol Biol Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Prog. Neuropsychopharmacol. Biol. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Progress in neuro-psychopharmacology &amp; biological psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0278-5846</issn>
<issn pub-type="epub">1878-4216</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27072377</article-id>
<article-id pub-id-type="pmc">5292013</article-id>
<article-id pub-id-type="doi">10.1016/j.pnpbp.2016.03.010</article-id>
<article-id pub-id-type="manuscript">NIHMS782542</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Diagnostic and therapeutic potential of microRNAs in neuropsychiatric disorders: Past, present, and future</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Alural</surname>
<given-names>Begum</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Genc</surname>
<given-names>Sermin</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haggarty</surname>
<given-names>Stephen J.</given-names>
</name>
<xref ref-type="aff" rid="A3">c</xref>
<xref ref-type="aff" rid="A4">d</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Department of Neuroscience, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey</aff>
<aff id="A2"><label>b</label>Izmir Biomedicine and Genome Center, Dokuz Eylul University, Izmir, Turkey</aff>
<aff id="A3"><label>c</label>Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA</aff>
<aff id="A4"><label>d</label>Chemical Neurobiology Laboratory, Departments of Neurology and Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA</aff>
<author-notes>
<corresp id="cor1"><label>*</label>Corresponding author at: Chemical Neurobiology Laboratory, Departments of Neurology and Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA., <email>shaggarry@mgh.harvard.edu</email> (S.J. Haggarty)</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>1</day>
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>09</day>
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<day>06</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>06</day>
<month>2</month>
<year>2018</year>
</pub-date>
<volume>73</volume>
<fpage>87</fpage>
<lpage>103</lpage>
<!--elocation-id from pubmed: 10.1016/j.pnpbp.2016.03.010-->
<abstract>
<p id="P1">Neuropsychiatry disorders are common health problems affecting approximately 1% of the population. Twin, adoption, and family studies have displayed a strong genetic component for many of these disorders; however, the underlying pathophysiological mechanisms and neural substrates remain largely unknown. Given the critical need for new diagnostic markers and disease-modifying treatments, expanding the focus of genomic studies of neuropsychiatric disorders to include the role of non-coding RNAs (ncRNAs) is of growing interest. Of known types of ncRNAs, microRNAs (miRNAs) are 20â€“25-nucleotide, single-stranded, molecules that regulate gene expression through post-transcriptional mechanisms and have the potential to coordinately regulate complex regulatory networks. In this review, we summarize the current knowledge on miRNA alteration/dysregulation in neuropsychiatric disorders, with a special emphasis on schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD). With an eye toward the future, we also discuss the diagnostic and prognostic potential of miRNAs for neuropsychiatric disorders in the context of personalized treatments and network medicine.</p>
</abstract>
<kwd-group>
<kwd>Non-coding RNA</kwd>
<kwd>MiRNA</kwd>
<kwd>Schizophrenia</kwd>
<kwd>Bipolar disorder</kwd>
<kwd>Neuroplasticiry</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>